Article
CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients.
Scientific reports - 28 Jan 2016
Su Shu, Hu Bian, Shao Jie, Shen Bin, Du Juan, Du Yinan, Zhou Jiankui, Yu Lixia, Zhang Lianru, Chen Fangjun, Sha Huizi, Cheng Lei, Meng Fanyan, Zou Zhengyun, Huang Xingxu, Liu Baorui
Abstract excerpt
Strategies that enhance the function of T cells are critical for immunotherapy. One negative regulator of T-cell activity is ligand PD-L1, which is expressed on dentritic cells (DCs) or some tumor cells, and functions through binding of programmed death-1 (PD-1) receptor on activated T cells. Here we described for the first time a non-viral mediated approach to reprogram primary human T cells by disruption of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.